After scouring 200 companies’ pipelines — including a few overlooked pharma shelves — a new company backed by investment firm Population Health Partners and ARCH Venture Partners is launching with one of the most wide-ranging pipelines yet for obesity drug development.
Metsera came out of stealth mode Thursday with $290 million in seed and Series A financing. ARCH and Population Health Partners, which launched in 2020 and has several veterans from Pfizer and The Medicines Company on its team, led the round. F-Prime Capital, GV, Mubadala Capital, Newpath Partners, and SoftBank Vision Fund 2 were also part of the financing.
Metsera has already put that money to work: The New York startup licensed several drug candidates from South Korean biotech D&D Pharmatech, according to Endpoints and Korea Biomedical Review. Altogether, the deal is worth more than 1 trillion Korean won, or $740 million, in licensing fees and milestone payments.
Click this link for the original source of this article.
Author: Allison DeAngelis
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.